A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Pharmacodynamics; Therapeutic Use
- 24 Jun 2011 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2008 Results of a subanalysis of biomarkers have been published in Journal of Rheumatology.